Review



interleukin 13  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    MedChemExpress interleukin 13
    Interleukin 13, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 8 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/interleukin+13/IL-13%2C+Human/pm42002048-273-57-59
    Average 95 stars, based on 8 article reviews
    interleukin 13 - by Bioz Stars, 2026-10
    95/100 stars

    Images

    Related Articles

    other:

    Article Title: METTL14 knockdown augmented the polarization of M2-like macrophages to promote acute myeloid leukemia progression.
    Article Snippet: Within the m6A methyltransferase complex, methyltransferase-like 14 (METTL14) constitutes a pivotal component.. This study aims to elucidate the role of METTL14 in macrophage differentiation and its involvement in the progression of acute myeloid leukemia (AML) through the modulation of programmed cell death-ligand 1 (PD-L1) expression in M2-like macrophages.. The expression levels of METTL14 in M1-like and M2-like macrophages were quantified using real-time quantitative polymerase chain reaction (QRT-PCR).

    Article Title: Panax notoginseng saponin mitigates glycolysis to regulate macrophage polarization and sphingolipid metabolism via hypoxia-inducible factor-1 to alleviate atherosclerosis.
    Article Snippet: In RAW264.7 cells, M2 polarization was induced by interleukin-4 treatment at 100 ng/ml (Cat: HY-P70653, MCE, China) and interleukin-13 at 100 ng/ml (Cat: HY-P70460, MCE, China) for 24 h. M1 polarization was induced by the treatment with interferon-γ at 2.5 ng/ ml (Cat: HY-P7071, MCE, China) and LPS (200 ng/ml (Cat: HY-D1056, MCE, China) for 24 h.

    Article Title: Mendelian randomization and multi-omics analysis identify C4A as a critical protective biomolecule in head and neck squamous cell carcinoma
    Article Snippet: Head and neck cancer (HNC) is a genetically complex malignancy and the sixth most common cancer worldwide, with increasing incidence rates.. Head and neck squamous cell carcinoma (HNSC) accounts for approximately 90% of HNC cases, often diagnosed at advanced stages, leading to high rates of recurrence and metastasis.. This study aims to identify novel therapeutic targets for HNC through a systematic genome-wide Mendelian randomization (MR) analysis of druggable genes.

    Article Title: Spatial Transcriptomics Reveals Transcriptomic and Immune Microenvironment Reprogramming during Thyroid Carcinoma Dedifferentiation.
    Article Snippet: After a 24-h resting period, cells were further stimulated with interleukin-4 (IL-4, MCE, HY-P70653, 20 ng ml−1) and interleukin-13 (IL-13, MCE, HYP72595, 20 ngml−1) for an additional 48 h to promote polarization toward the M2 phenotype.

    Article Title: M2 macrophage-derived exosomes deliver NGF-modified mRNA to promote comprehensive corneal repair.
    Article Snippet: The cornea is a unique tissue vital for vision but susceptible to various injuries.. Given this complexity, effective regeneration following severe damage requires the coordinated restoration of multiple tissue components, underscoring the need for innovative therapeutic strategies. mRNA technology has emerged as a transformative platform for protein delivery and therapeutic intervention.. Chemically modified mRNA (modRNA), with its enhanced stability and reduced immunogenicity, enables transient yet highly efficient protein expression, positioning it as a powerful tool for therapeutic applications.

    Article Title: Spatial Transcriptomics Reveals Transcriptomic and Immune Microenvironment Reprogramming during Thyroid Carcinoma Dedifferentiation
    Article Snippet: After a 24‐h resting period, cells were further stimulated with interleukin‐4 (IL‐4, MCE, HY‐ P70653 , 20 ng ml −1 ) and interleukin‐13 (IL‐13, MCE, HY‐ P72595 , 20 ng ml −1 ) for an additional 48 h to promote polarization toward the M2 phenotype.

    Generated:

    Article Title: Integrating necroptosis and immune landscapes: a multi-omics-derived NecropImmScore stratifies prognosis and therapy in ovarian cancer.
    Article Snippet: Co‐culture of OC cell lines with THP‐1 cells and human jurkat clone E6‐1 T cells THP-1 monocytes (5 × 104 cells/well) were plated in 6-well culture dishes (Corning, USA) and polarized into M0 macrophages via 48 h exposure to 100 ng/ml phorbol12-myristate-13-acetate (PMA; MedChemExpress, China). .. Subsequently, M1 macrophage differentiation was induced by stimulating M0 cells with 100 ng/ml lipopolysaccharide (LPS; PeproTech, USA) for 48 h, while M2 macrophages were generated by exposing M0 macrophages to 20 ng/ml interleukin-4 (IL-4, MedChemExpress, China) and 20 ng/ml interleukin-13 (IL-13, MedChemExpress, China) for 48 h. For co-culture experiments, a Transwell® system (Corning, USA) featuring 0.4 μm microporous membranes was employed. ..

    Article Title: Integrating necroptosis and immune landscapes: a multi-omics-derived NecropImmScore stratifies prognosis and therapy in ovarian cancer
    Article Snippet: THP-1 monocytes (5 × 10 4 cells/well) were plated in 6-well culture dishes (Corning, USA) and polarized into M 0 macrophages via 48 h exposure to 100 ng/ml phorbol-12-myristate-13-acetate (PMA; MedChemExpress, China). .. Subsequently, M 1 macrophage differentiation was induced by stimulating M 0 cells with 100 ng/ml lipopolysaccharide (LPS; PeproTech, USA) for 48 h, while M 2 macrophages were generated by exposing M 0 macrophages to 20 ng/ml interleukin-4 (IL-4, MedChemExpress, China) and 20 ng/ml interleukin-13 (IL-13, MedChemExpress, China) for 48 h. For co-culture experiments, a Transwell® system (Corning, USA) featuring 0.4 μm microporous membranes was employed. ..



    Similar Products

    mouse il-13 (interleukin 13) elisa kit  (Guangzhou JET Bio-Filtration)
    94
    Guangzhou JET Bio-Filtration mouse il-13 (interleukin 13) elisa kit
    Mouse Il 13 (Interleukin 13) Elisa Kit, supplied by Guangzhou JET Bio-Filtration, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/interleukin+13/Mouse+IL-13+(Interleukin+13)+ELISA+Kit/custom%40e-el-m0727%4042002123
    Average 94 stars, based on 1 article reviews
    mouse il-13 (interleukin 13) elisa kit - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    il 13  (Elabscience Biotechnology)
    94
    Elabscience Biotechnology il 13
    Il 13, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/interleukin+13/Mouse+IL-13+(Interleukin+13)+ELISA+Kit/pm42853894-435-11-19
    Average 94 stars, based on 1 article reviews
    il 13 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    serum ige  (Shanghai Korain Biotech Co Ltd)
    94
    Shanghai Korain Biotech Co Ltd serum ige
    Serum Ige, supplied by Shanghai Korain Biotech Co Ltd, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/interleukin+13/Human+Interleukin+13/10__3390_slash_vetsci13100998-92-0-6
    Average 94 stars, based on 1 article reviews
    serum ige - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    canine il 13  (Shanghai Korain Biotech Co Ltd)
    96
    Shanghai Korain Biotech Co Ltd canine il 13
    Canine Il 13, supplied by Shanghai Korain Biotech Co Ltd, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/interleukin+13/Canine+Interleukin+13/10__3390_slash_vetsci13100998-93-29-34
    Average 96 stars, based on 1 article reviews
    canine il 13 - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    recombinant human interleukin 13  (InvivoGen)
    94
    InvivoGen recombinant human interleukin 13
    Recombinant Human Interleukin 13, supplied by InvivoGen, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/interleukin+13/Recombinant+human+IL-13/pm42430880-45-61-69
    Average 94 stars, based on 1 article reviews
    recombinant human interleukin 13 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    elisa kits  (Elabscience Biotechnology)
    94
    Elabscience Biotechnology elisa kits
    Elisa Kits, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/interleukin+13/Mouse+IL-13+(Interleukin+13)+ELISA+Kit/pm42002123-99-5-12
    Average 94 stars, based on 1 article reviews
    elisa kits - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    interleukin 13  (MedChemExpress)
    95
    MedChemExpress interleukin 13
    Interleukin 13, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/interleukin+13/IL-13%2C+Human/pm42002048-273-57-59
    Average 95 stars, based on 1 article reviews
    interleukin 13 - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    cytokines il 13  (Elabscience Biotechnology)
    94
    Elabscience Biotechnology cytokines il 13
    Cytokines Il 13, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/interleukin+13/Mouse+IL-13+(Interleukin+13)+ELISA+Kit/pm42002123-99-9-12
    Average 94 stars, based on 1 article reviews
    cytokines il 13 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    interleukin 13 il 13  (MedChemExpress)
    95
    MedChemExpress interleukin 13 il 13
    THP-1 cells were treated under different conditions: PMA (50 ng/ml) alone, or PMA (50 ng/ml) for 24 hours, followed by a medium change and subsequent treatment with IL-4 (20 ng/ml) <t>and</t> <t>IL-13</t> (20 ng/ml) for 48 hours. After this, the medium was replaced with RPMI 1640 medium without FBS for 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) Morphological features of THP-1 cells under different conditions. Left: untreated THP-1 cells. Middle: PMA (50 ng/ml) for 24 hours. Right: PMA for 24 hours, followed by IL-4 and IL-13 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. Scale bar: 50 μm. (B) Relative expression of Arg1 mRNA. (C) Relative expression of Arg1 protein. (D) Concentrations of TNF and IL-10 in the supernatant. (E) Relative mRNA expression of JMJD3 and IRF4. (F) Protein expression of JMJD3, p-STAT6-Y641, and IRF4. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: Arg1, arginase 1; PMA, Phorbol 12-myristate 13-acetate; IL-10, interleukin-10; TNF, tumor necrosis factor; JMJD3, Jumonji domain-containing protein 3; IRF4, interferon regulatory factor 4; p-STAT6, phosphorylated signal transducer and activator of transcription 6.
    Interleukin 13 Il 13, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/interleukin+13/IL-13%2C+Human/pmc13065056-41-18-23
    Average 95 stars, based on 1 article reviews
    interleukin 13 il 13 - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    THP-1 cells were treated under different conditions: PMA (50 ng/ml) alone, or PMA (50 ng/ml) for 24 hours, followed by a medium change and subsequent treatment with IL-4 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. After this, the medium was replaced with RPMI 1640 medium without FBS for 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) Morphological features of THP-1 cells under different conditions. Left: untreated THP-1 cells. Middle: PMA (50 ng/ml) for 24 hours. Right: PMA for 24 hours, followed by IL-4 and IL-13 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. Scale bar: 50 μm. (B) Relative expression of Arg1 mRNA. (C) Relative expression of Arg1 protein. (D) Concentrations of TNF and IL-10 in the supernatant. (E) Relative mRNA expression of JMJD3 and IRF4. (F) Protein expression of JMJD3, p-STAT6-Y641, and IRF4. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: Arg1, arginase 1; PMA, Phorbol 12-myristate 13-acetate; IL-10, interleukin-10; TNF, tumor necrosis factor; JMJD3, Jumonji domain-containing protein 3; IRF4, interferon regulatory factor 4; p-STAT6, phosphorylated signal transducer and activator of transcription 6.

    Journal: PLOS One

    Article Title: JMJD3 regulates the M2-like macrophage polarization and promotes the growth of breast cancer cells via STAT6/IRF4 axis

    doi: 10.1371/journal.pone.0341313

    Figure Lengend Snippet: THP-1 cells were treated under different conditions: PMA (50 ng/ml) alone, or PMA (50 ng/ml) for 24 hours, followed by a medium change and subsequent treatment with IL-4 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. After this, the medium was replaced with RPMI 1640 medium without FBS for 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) Morphological features of THP-1 cells under different conditions. Left: untreated THP-1 cells. Middle: PMA (50 ng/ml) for 24 hours. Right: PMA for 24 hours, followed by IL-4 and IL-13 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. Scale bar: 50 μm. (B) Relative expression of Arg1 mRNA. (C) Relative expression of Arg1 protein. (D) Concentrations of TNF and IL-10 in the supernatant. (E) Relative mRNA expression of JMJD3 and IRF4. (F) Protein expression of JMJD3, p-STAT6-Y641, and IRF4. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: Arg1, arginase 1; PMA, Phorbol 12-myristate 13-acetate; IL-10, interleukin-10; TNF, tumor necrosis factor; JMJD3, Jumonji domain-containing protein 3; IRF4, interferon regulatory factor 4; p-STAT6, phosphorylated signal transducer and activator of transcription 6.

    Article Snippet: Subsequently, the cells were treated with 20 ng/ml interleukin-4 (IL-4) (200-04-02; PeproTech, Cranbury, NJ, USA) and 20 ng/ml interleukin-13 (IL-13) (HY- P70568 ; MCE, Monmouth Junction, NJ, USA).

    Techniques: Expressing

    (A) THP-1 cells were infected with shJMJD3 or oeJMJD3 lentiviruses for 72 hours. JMJD3 mRNA expression was then assessed. shCtrl and oeCtrl: negative control lentiviruses. shJMJD3: THP-1 cells infected with lentiviruses to knockdown JMJD3. oeJMJD3: THP-1 cells infected with lentiviruses to overexpress JMJD3. Following lentivirus infection, THP-1 cells were treated with PMA for 24 hours, followed by IL-4 and IL-13 for 48 hours. After this, the medium was replaced by RPMI 1640 medium without FBS for an additional 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (B) Relative expression of Arg1 mRNA. (C) Concentrations of TNF in the supernatant of different groups of macrophages. (D) Relative expression of IRF4 mRNA. (E, F) Western blot analysis of CD206, JMJD3, and IRF4 protein. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: JMJD3, Jumonji domain-containing protein 3; Arg1, arginase 1; TNF, tumor necrosis factor; IRF4, interferon regulatory factor 4; CD206, cluster of differentiation 206.

    Journal: PLOS One

    Article Title: JMJD3 regulates the M2-like macrophage polarization and promotes the growth of breast cancer cells via STAT6/IRF4 axis

    doi: 10.1371/journal.pone.0341313

    Figure Lengend Snippet: (A) THP-1 cells were infected with shJMJD3 or oeJMJD3 lentiviruses for 72 hours. JMJD3 mRNA expression was then assessed. shCtrl and oeCtrl: negative control lentiviruses. shJMJD3: THP-1 cells infected with lentiviruses to knockdown JMJD3. oeJMJD3: THP-1 cells infected with lentiviruses to overexpress JMJD3. Following lentivirus infection, THP-1 cells were treated with PMA for 24 hours, followed by IL-4 and IL-13 for 48 hours. After this, the medium was replaced by RPMI 1640 medium without FBS for an additional 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (B) Relative expression of Arg1 mRNA. (C) Concentrations of TNF in the supernatant of different groups of macrophages. (D) Relative expression of IRF4 mRNA. (E, F) Western blot analysis of CD206, JMJD3, and IRF4 protein. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: JMJD3, Jumonji domain-containing protein 3; Arg1, arginase 1; TNF, tumor necrosis factor; IRF4, interferon regulatory factor 4; CD206, cluster of differentiation 206.

    Article Snippet: Subsequently, the cells were treated with 20 ng/ml interleukin-4 (IL-4) (200-04-02; PeproTech, Cranbury, NJ, USA) and 20 ng/ml interleukin-13 (IL-13) (HY- P70568 ; MCE, Monmouth Junction, NJ, USA).

    Techniques: Infection, Expressing, Negative Control, Knockdown, Western Blot

    THP-1 cells were first treated with PMA for 24 hours. Following this, AS1517499 (1μM) was administered for 30 minutes, and then the cells were treated with IL-4 and IL-13. 48 hours later, the medium was replaced with RPMI 1640 medium without FBS and cells were incubated for an additional 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) The mRNA expression of Arg1. (B) Concentrations of TNF in the supernatant of different groups of macrophages. (C) Concentrations of IL-10 in the supernatant of different groups of macrophages. (D) Expression of IRF4 mRNA. (E) Expression of JMJD3 mRNA. (F) Western blot analysis of JMJD3, p-STAT6, and IRF4 protein expression. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: JMJD3, Jumonji domain-containing protein 3; Arg1, arginase 1; TNF, tumor necrosis factor; IRF4, interferon regulatory factor 4; IL-10, interleukin-10; p-STAT6, phosphorylated signal transducer and activator of transcription 6.

    Journal: PLOS One

    Article Title: JMJD3 regulates the M2-like macrophage polarization and promotes the growth of breast cancer cells via STAT6/IRF4 axis

    doi: 10.1371/journal.pone.0341313

    Figure Lengend Snippet: THP-1 cells were first treated with PMA for 24 hours. Following this, AS1517499 (1μM) was administered for 30 minutes, and then the cells were treated with IL-4 and IL-13. 48 hours later, the medium was replaced with RPMI 1640 medium without FBS and cells were incubated for an additional 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) The mRNA expression of Arg1. (B) Concentrations of TNF in the supernatant of different groups of macrophages. (C) Concentrations of IL-10 in the supernatant of different groups of macrophages. (D) Expression of IRF4 mRNA. (E) Expression of JMJD3 mRNA. (F) Western blot analysis of JMJD3, p-STAT6, and IRF4 protein expression. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: JMJD3, Jumonji domain-containing protein 3; Arg1, arginase 1; TNF, tumor necrosis factor; IRF4, interferon regulatory factor 4; IL-10, interleukin-10; p-STAT6, phosphorylated signal transducer and activator of transcription 6.

    Article Snippet: Subsequently, the cells were treated with 20 ng/ml interleukin-4 (IL-4) (200-04-02; PeproTech, Cranbury, NJ, USA) and 20 ng/ml interleukin-13 (IL-13) (HY- P70568 ; MCE, Monmouth Junction, NJ, USA).

    Techniques: Incubation, Expressing, Western Blot